Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04494893 · ClinicalTrials.gov registry record
ImmuneRACE - Immune Response Action to COVID-19 Events
A clinical trial, sponsored by Adaptive Biotechnologies.
- Completed
- Registry status
- 808
- Enrollment target
NCT04494893: Completed study, sponsored by Adaptive Biotechnologies.
NCT04494893 is a clinical trial that has completed, run by Adaptive Biotechnologies. The registered enrollment target is 808 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04494893 has completed, sponsored by Adaptive Biotechnologies.
- COMPLETED
- Registry status
- 808 participants
- Enrollment target
Study Summary
ImmuneRACE is a study, which is designed to better understand the immune response to COVID-19. This is critically important because the immune system may be able to tell us important information about how our own bodies detect and respond to the disease that current tests cannot. De-identified data collected from this study may accelerate the development of better diagnostics for COVID-19 and improve outcomes for many.
Primary Outcome
We will run immunoSEQ on approximately 1000 patient samples with disease status unblinded. After sequencing these samples, we will quantitatively describe the compartment of the T-cell repertoire specific for the disease of interest. We will then use these data to construct a classifier that accurately distinguishes patients from controls.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 808 participants |
| Start Date | 2020-04-24 |
| Est. Completion | 2021-04-23 |
What the finished NCT04494893 record still lists
NCT04494893 is an observational study that tracks outcomes without assigning an intervention. The registered 808 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04494893 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04494893 about?
NCT04494893 is a clinical study titled "ImmuneRACE - Immune Response Action to COVID-19 Events". ImmuneRACE is a study, which is designed to better understand the immune response to COVID-19. This is critically important because the immune system may be able to tell us important information about how our own bodies detect and respond to the disease that current tests cannot. De-identified data ...
What is the current status of trial NCT04494893?
This trial is currently completed. The enrollment target is 808 participants. The study started on 2020-04-24. Estimated completion is 2021-04-23.
Who is sponsoring clinical trial NCT04494893?
This trial is sponsored by Adaptive Biotechnologies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT05519085 · 810 participants · Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- NCT06065098 · 806 participants · NA
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI